Observational study on Wilson's Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the clinical spectrum and natural progression of Wilson's Disease through a multicenter observational approach. It will assess various clinical, genetic, and epigenetic features, as well as biomarkers in patients diagnosed with Wilson's Disease. The goal is to gather comprehensive data that can optimize clinical management for affected individuals. Participants will include patients, asymptomatic carriers, relatives, and healthy controls.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with the genetic diagnosis of Wilson's Disease
* Asymptomatic Wilson's Disease carriers
* Relatives of Wilson's Disease patients or carriers
* Unrelated healthy controls
* Participants or Parent(s)/legal guardian(s) willing and able to complete the informed consent process

Exclusion Criteria:

\* Participants are unable to comply with study procedures and visit schedule

Where it's running

• First Affiliated Hospital of Fujian Medical University
  Fuzhou, China Recruiting

Study contacts

• Study coordinator: Jin He, MD
• Email: hejinfjmu@hotmail.com
• Phone: 86-0591-87982772

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PM577a: a one-time gene-editing therapy for Wilson disease

  This study tests PM577a, a gene-editing treatment, to see if it is safe and may help people with Wilson disease who have a p.H1069Q ATP7B mutation.

  Recruiting at 2 sites Phase 1/2 Prime Medicine, Inc. · New Haven, Connecticut and 3 other locations · NCT07748403

• One-a-day trientine for newly diagnosed Wilson's disease

  A new once-daily trientine formulation is being tested against d-Penicillamine as a first-line treatment for people with Wilson's disease, including both children 8 and older and adults.

  Recruiting at 5 sites Phase 3 Orphalan · Denver, Colorado and 9 other locations · NCT07465718

• ATP7B mRNA (DSL101) therapy for Wilson disease

  This treatment will test whether one or more IV infusions of ATP7B mRNA (DSL101) are safe and help control copper in adults with genetically confirmed Wilson disease.

  Recruiting Early Phase 1 DSciLab Co., Ltd. · Hefei, Anhui · NCT07240896

• Investigating heart issues in Wilson's Disease

  This study is testing how Wilson's Disease affects the heart in adults by using long-term heart monitoring to see if copper buildup causes any problems.

  Recruiting Fondation Ophtalmologique Adolphe de Rothschild · Paris · NCT05493605

• International registry for Wilson's Disease patients

  This study is gathering information from people with Wilson's Disease during their regular doctor visits to better understand the disease and how patients are managing it.

  Recruiting at 16 sites Orphalan · Leuven and 15 other locations · NCT05239858

• Examining copper levels in breast milk of pregnant women with Wilson's disease

  This study tests how treatment for Wilson's disease affects copper levels in the breast milk of pregnant women to ensure the health of both mom and baby during breastfeeding.

  Recruiting Fondation Ophtalmologique Adolphe de Rothschild · Paris · NCT05183165

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.